CRISPR Therapeutics (CRSP) to Release Earnings on Wednesday

CRISPR Therapeutics (NASDAQ:CRSP) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. The company’s revenue for the quarter was up 71.6% on a year-over-year basis. During the same quarter last year, the company earned ($1.43) earnings per share. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Stock Down 11.7 %

Shares of NASDAQ CRSP opened at $33.21 on Wednesday. CRISPR Therapeutics has a twelve month low of $30.04 and a twelve month high of $67.88. The company has a market cap of $2.87 billion, a PE ratio of -7.60 and a beta of 1.88. The business’s 50 day moving average price is $38.62 and its two-hundred day moving average price is $43.00.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on CRSP shares. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, April 9th. Citigroup decreased their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a research note on Tuesday, February 18th. HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Finally, Chardan Capital lowered their target price on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $73.11.

Insider Activity

In other news, CEO Samarth Kulkarni sold 9,973 shares of the business’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the transaction, the chief executive officer now owns 180,890 shares of the company’s stock, valued at approximately $7,673,353.80. The trade was a 5.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Greene acquired 7,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 26th. The stock was acquired at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the purchase, the director now directly owns 7,000 shares of the company’s stock, valued at $313,950. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is currently owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.